Docetaxel, Doxorubicin, Cyclophosphamide

DRUG3 trials

Sponsors

Sanofi, Peking Union Medical College Hospital

Conditions

Breast Cancer

Phase 2

DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer

CompletedNCT02838225

Peking Union Medical College HospitalBreast Cancer

Start: 2009-01-31Updated: 2016-07-20

Phase 3

Docetaxel in Breast Cancer

CompletedNCT00312208

SanofiBreast Cancer

Start: 2001-11-30End: 2013-10-31Updated: 2013-12-30

TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer

CompletedNCT01354522

Peking Union Medical College HospitalBreast Cancer

Start: 2011-05-31End: 2023-12-31Updated: 2025-06-15

Related Papers

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

The Oncologist2025-08-21

Abstract P5-08-06: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide (TCX) versus anthracycline plus docetaxel & cyclophosphamide regimen (TAC) in women with high-risk, Her2-negative breast cancer: an open-label, randomized controlled trial

Clinical Cancer Research2025-06-13

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high‐risk, HER2‐negative breast cancer: An open‐label, randomized controlled trial

Cancer Communications2025-06-09

Adjuvant regional nodal irradiation did not improve outcomes in T1-2N1 breast cancer after breast-conserving surgery: A propensity score matching analysis of BIG02/98 and BCIRG005 trials.

2019-11-297 citations

Impact of Regional Nodal Irradiation on the Outcomes of N1 Breast Cancer Patients Referred for Adjuvant Treatment: A Patient-Level Pooled Analysis of 2 Clinical Trials.

2018-07-245 citations

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

2016-03-0246 citations